Bluejay Diagnostics (BJDX) Net Equity Issued and Repurchased (2020 - 2026)

Bluejay Diagnostics (BJDX) posted Net Equity Issued and Repurchased of $125000.0 for Q1 2026, down 97.22% sequentially from $4.5 million in Q4 2025.

Bluejay Diagnostics (BJDX) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends

Bluejay Diagnostics has reported Net Equity Issued and Repurchased for 4 years, with the latest figure at $125000.0 in Q1 2026.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $125000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (changed N/A YoY) and the FY2025 annual result came in at $8.3 million, down 30.84% from the prior year.
Net Equity Issued and Repurchased declined to $125000.0 in Q1 2026 per BJDX's latest filing, from $4.5 million in the prior quarter.
Over five years, Net Equity Issued and Repurchased peaked at $8.6 million in Q2 2024 and troughed at $125000.0 in Q1 2026.
A 3-year average of $4.2 million and a median of $4.0 million in 2024 frame the typical range for Net Equity Issued and Repurchased.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Abbott Laboratories	202.72 Bn	197.12 Bn	7.27 Bn	-
2	Stryker	126.42 Bn	122.94 Bn	4.50 Bn	-
3	Medtronic	119.75 Bn	110.53 Bn	6.41 Bn	97.00 Mn
4	Boston Scientific	74.13 Bn	73.60 Bn	3.85 Bn	-
5	Edwards Lifesciences	51.78 Bn	47.53 Bn	1.35 Bn	-
6	Dexcom	35.29 Bn	33.34 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.95 Bn	31.85 Bn	2.18 Bn	-
8	Koninklijke Philips	26.22 Bn	22.90 Bn	4.55 Bn	-
9	Steris	23.21 Bn	22.73 Bn	684.20 Mn	-
10	Bluejay Diagnostics	1.89 Mn	1.89 Mn	-	8.50 Mn

Download Data